[{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$688.0 million","upfrontCash":"$443.3 million","newsHeadline":"BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.68999999999999995,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$548.6 million","upfrontCash":"$548.6 million","newsHeadline":"BioNTech Completes Acquisition of InstaDeep","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.55000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"}]

Find Clinical Drug Pipeline Developments & Deals by InstaDeep

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : The acquisition will enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging AI and machine learning technologies across BioNTech’s therapeutic platforms a...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : $548.6 million

                          July 31, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : BioNTech

                          Deal Size : $548.6 million

                          Deal Type : Acquisition

                          blank

                          02

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : The acquisition will enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by leveraging AI and machine learning technologies across BioNTech’s therapeutic platforms a...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : $443.3 million

                          January 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : BioNTech

                          Deal Size : $688.0 million

                          Deal Type : Acquisition

                          blank